# US 2016/0257962 A1 · Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257962 A1
- Document ID: US20160257962A1
- Status: Published application
- Kind: A1
- Application number: 15/070,302
- Filed: 2016-03-15
- Published: 2016-09-08
- Earliest claimed: 2011-06-06
- Assignees: Sirna Therapeutics, Inc.
- Applicants: Sirna Therapeutics, Inc.
- Inventors: Yong Ma; Duncan Brown; Steven Bartz
- Web page: https://patentgrep.com/patent/US20160257962A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 21/02: with ribosyl as saccharide radical
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/332: Abasic residue
- C12N 2310/3521: Methyl
- C12N 2310/3533: Halogen
- C12Y 101/01042: Isocitrate dehydrogenase (NADP+) (1.1.1.42)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Y: ENZYMES

## Abstract

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of IDH1 and mutant IDH1 gene expression and/or activity, and/or modulate an IDH1 or mutant IDH1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules, including small nucleic acid molecules such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, that are capable of mediating or that mediate RNA interference (RNAi) against IDH1 or mutant IDH1 gene expression.

## Claims

### Claim at position 1

-40. (canceled)

### Claim 41

An isolated double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of IDH1 or mutant IDH1, wherein:
(a) the siNA comprises a sense strand and an antisense strand;
(b) each strand is independently 15 to 30 nucleotides in length; and,
(c) at least one strand comprises at least a 15 nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-506.

### Claim 42 (depends on 1)

A double-stranded siNA molecule of claim 1, wherein:
the antisense strand comprises at least 15 nucleotides having sequence complementary to any of:
(SEQ ID NO: 7)
5′-CUAUCAUCAUAGGUCGUCA-3′;
(SEQ ID NO: 11)
5′-CAUCAUAGGUCGUCAUGCU-3′;
(SEQ ID NO: 12)
5′-AUCAUAGGUCGUCAUGCUU-3′;
(SEQ ID NO: 13)
5′-UCAUAGGUCGUCAUGCUUA-3′;
(SEQ ID NO: 38)
5′-CAUCAUAGGUUGUCAUGCU-3′;
(SEQ ID NO: 39)
5′-AUCAUAGGUUGUCAUGCUU-3′;
(SEQ ID NO: 40)
5′-UCAUAGGUUGUCAUGCUUA-3′;
(SEQ ID NO: 41)
5′-CAUAGGUUGUCAUGCUUAU-3′;
(SEQ ID NO: 59)
5′-CAUAGGUCAUCAUGCUUAU-3′;
or,
(SEQ ID NO: 63)
5′-GGUCAUCAUGCUUAUGGGG-3′.

### Claim 43 (depends on 41)

A double-stranded siNA molecule of claim 41, wherein the siNA comprises any of:
(SEQ ID NO: 7)
5′-CUAUCAUCAUAGGUCGUCA-3′
and
SEQ ID NO: 446)
5′-UGACGACCUAUGAUGAUAG-3′;
(SEQ ID NO: 11)
5′-CAUCAUAGGUCGUCAUGCU-3′
and
(SEQ ID NO: 450)
5′-AGCAUGACGACCUAUGAUG-3′;
(SEQ ID NO: 12)
5′-AUCAUAGGUCGUCAUGCUU-3′
and
(SEQ ID NO: 451)
5′-AAGCAUGACGACCUAUGAU-3′;
(SEQ IN NO: 13)
5′-UCAUAGGUCGUCAUGCUUA-3′
and
(SEQ ID NO: 452)
5′-UAAGCAUGACGACCUAUGA-3′;
(SEQ ID NO: 38)
5′-CAUCAUAGGUUGUCAUGCU-3′
and
(SEQ ID NO: 477)
5′-AGCAUGACAACCUAUGAUG-3 ′;
(SEQ ID NO: 39)
5′-AUCAUAGGUUGUCAUGCUU-3′
and
(SEQ ID NO: 478)
5′-AAGCAUGACAACCUAUGAU-3′;
(SEQ ID NO: 40)
5′-UCAUAGGUUGUCAUGCUUA-3′
and
(SEQ ID NO: 479)
5′-UAAGCAUGACAACCUAUGA-3′;
(SEQ ID NO: 41)
5′-CAUAGGUUGUCAUGCUUAU-3′
and
(SEQ ID NO: 480)
5′-AUAAGCAUGACAACCUAUG-3 ′;
(SEQ ID NO: 59)
5′-CAUAGGUCAUCAUGCUUAU-3′
and
(SEQ ID NO: 498)
5′-AUAAGCAUGAUGACCUAUG-;
or,
(SEQ ID NO: 63)
5′-GGUCAUCAUGCUUAUGGGG-3′
and
(SEQ ID NO: 502)
5′-CCCCAUAAGCAUGAUGACC-3′.

### Claim 44 (depends on 41)

A double-stranded siNA molecule of claim 41, wherein at least one nucleotide is a chemically modified nucleotide.

### Claim 45 (depends on 41)

A double-stranded siNA molecule of claim 41 comprising at least one phosphorothioate internucleotide linkage.

### Claim 46 (depends on 41)

A double-stranded siNA molecule of claim 41 comprising a cap on the 3′-end, 5′-end, or both 3′ and 5′ ends of at least one strand.

### Claim 47 (depends on 41)

A double-stranded siNA molecule of claim 41 comprising one or more 3′-overhang nucleotides on one or both strands.

### Claim 48 (depends on 41)

A double-stranded siNA molecule of claim 41, wherein the 5′-end of the antisense strand is phosphorylated.

### Claim 49 (depends on 47)

A double-stranded siNA molecule of claim 47, wherein the 3′-overhang nucleotides on at least one strand are 2′-O-methyl nucleotides.

### Claim 50 (depends on 44)

A double-stranded siNA molecule of claim 44, wherein the at least one chemically modified nucleotide is a 2′-deoxy-2′-fluoro nucleotide.

### Claim 51 (depends on 44)

A double-stranded siNA molecule of claim 44, wherein the at least one chemically modified nucleotide is a 2′-deoxy nucleotide.

### Claim 52 (depends on 44)

A double-stranded siNA molecule of claim 44, wherein the at least one chemically modified nucleotide is a 2′-O-alkyl nucleotide.

### Claim 53

A double-stranded short interfering nucleic acid (siNA) molecule, comprising formula (A) having a sense strand and an antisense strand:
wherein, the upper strand is the sense strand and the lower strand is the antisense strand of the double-stranded nucleic acid molecule; wherein the antisense strand comprises at least a 15 nucleotide sequence of SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 452, SEQ ID NO: 477, SEQ ID NO: 478, SEQ ID NO: 479, SEQ ID NO: 480, SEQ ID NO: 498, or SEQ ID NO: 502; and the sense strand comprises a sequence having complementarity to the antisense strand;
each N is independently either a nucleotide that is unmodified or chemically modified, or a non-nucleotide;
each B is a terminal cap that is present or absent;
(N) represents overhanging nucleotides, each of which is independently unmodified or chemically modified; X1 and X2 are independently integers from 0 to 4;
X3 is an integer from 15 to 30;
X4 is an integer from 12 to 27; and,
[N1]-[N2]-[N3] are modified nucleotides or ribonucleotides, and wherein [N1]-[N2]-[N3] is selected from the groups consisting of:
(a) [N1] is a 2′-deoxy-2′-fluoro nucleotide, [N2] is a 2′-deoxy-2′-fluoro nucleotide, and [N3] is a 2′-deoxy-2′-fluoro nucleotide;
(b) [N1] is a 2′-deoxy-2′-fluoro nucleotide, [N2] is a 2′-deoxy-2′-fluoro nucleotide, and [N3] is a 2′-deoxy nucleotide;
(c) [N1] is a 2′-deoxy nucleotide, [N2] is a 2′-deoxy-2′-fluoro nucleotide, and [N3] is a 2′-O-methyl nucleotide;
(d) [N1] is a 2′-deoxy nucleotide, [N2] is a 2′-deoxy-2′-fluoro nucleotide, and [N3] is a 2′-deoxy nucleotide; and,
(e) [N1] is a ribonucleotide, [N2] is a ribonucleotide, and [N3] is a ribonucleotide.

### Claim 54 (depends on 53)

A double-stranded siNA molecule according to claim 53, wherein:
(a) one or more pyrimidine nucleotides in NX4 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any combination thereof;
(b) one or more purine nucleotides in NX4 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any combination thereof;
(c) one or more pyrimidine nucleotides in NX3 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any combination thereof and,
(d) one or more purine nucleotides in NX3 positions are independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any combination thereof.

### Claim 55 (depends on 53)

A double-stranded siNA molecule according to claim 53, wherein X1 is 2 and X2 is 2.

### Claim 56 (depends on 53)

A double-stranded siNA molecule according to claim 53, wherein each X1 and X2=1 or 2; X3=18, 19, 20, 21, 22, 23 or 24; and, X4=15, 16, 17, 18, 19, 20, or 21.

### Claim 57 (depends on 53)

A double-stranded siNA molecule according to claim 53, comprising one or more phosphorothioate internucleotide linkages.

### Claim 58 (depends on 41)

A composition comprising a double-stranded siNA molecule of claim 41 in a pharmaceutically acceptable carrier or diluent.

### Claim 59 (depends on 41, 58)

A method of treating a human subject suffering from a condition that is mediated by the action or loss of action of IDH1 or mutant IDH1, which comprises administering to said subject an effective amount of:
(a) a double-stranded siNA molecule according to claim 41; or,
(b) a composition according to claim 58.

### Claim 60 (depends on 59)

The method according to claim 59, wherein the condition is cancer.
